Dr. Chen Xiaobei, the first certified surgeon in China and Dongguan to perform EVO+ICL (V5) procedures, has successfully completed the city's inaugural V5 surgery.

On the morning of January 19, Chen Xiaobei, Director of the Refractive Surgery Department at Dongguan Aier Eye Hospital, successfully completed the newly upgraded EVO+ICL (V5) implant surgery. She was awarded the EVO+ICL (V5) Surgical Certification Expert Certificate by STAAR Surgical Company in the United States, becoming one of the first refractive surgeons nationwide and the first in Dongguan to receive this international certification.

Chen Xiaobei's team pioneered the clinical application of the large optical zone intraocular lens EVO+ICL (V5) technology, marking Dongguan's entry into a new era of “day-night vision enhancement + high definition” in myopia correction. This advancement offers local myopia patients more cutting-edge, diverse, and high-quality options for vision correction.

A New Leap in Intraocular Lens Surgery

Unveiling a New Chapter of “Day-Night Vision Enhancement + High Definition”

The first beneficiary of this surgery, Ms. Zhang (pseudonym), had 575 degrees of myopia with 150 degrees of astigmatism in her left eye and 875 degrees of myopia with 75 degrees of astigmatism in her right eye. She decided to undergo vision correction due to the inconvenience of daily glasses wear and her high demands for visual quality. After learning that ICL lens implantation boasts over 30 years of clinical application history with more than 3 million successful global implantations—its long-term safety, efficacy, and stability extensively validated—and that the EVO+ICL (V5) technology delivers significant upgrades in nighttime contrast sensitivity and visual quality, she firmly chose Director Chen Xiaobei to perform her V5 lens implantation.

Director Chen Xiaobei Performs First EVO+ICL(V5) Surgery

First Dongguan Doctor Receives Certification

Setting a Benchmark for Clinical Application

“ICL technology has long been a popular choice for myopia correction due to its reversibility and high-definition visual quality post-surgery,” Director Chen Xiaobei explained that as the latest iteration of ICL technology, EVO+ICL (V5) offers core advantages of “a larger optical zone and superior night vision.” It not only retains the reversibility and high-definition visual outcomes of ICL surgery but also significantly enhances nighttime visual quality through optimized optical design. This effectively reduces glare and halos, making it particularly suitable for individuals with high demands for night vision.

Reportedly, the V5 lens design expands the optical zone to effectively enhance nighttime contrast sensitivity while substantially reducing visual disturbances like glare and halos. This enables clear, comfortable vision during night driving, urban nightscape viewing, and evening reading. This technology boasts broad applicability, suitable for individuals with myopia ranging from -5.00 to -14.00 diopters and astigmatism not exceeding -6.00 diopters. It precisely addresses the core needs of those frequently using their eyes at night while also providing a refined, “custom-tailored” correction solution for patients with low to moderate myopia. This advances the precision of refractive correction and visual quality to new heights.

First Dongguan Doctor to Receive Certification

Setting a Benchmark for Clinical Application

The safety and long-term outcomes of ICL surgery heavily depend on the surgeon's profound expertise and clinical experience in preoperative assessment, intraoperative execution, and management of complex postoperative scenarios. As one of Dongguan's earliest refractive surgeons specializing in ICL technology, Director Chen Xiaobei brings 17 years of ophthalmic clinical experience, having performed over 30,000 myopia surgeries—including more than 5,000 ICL procedures. She has earned multiple international accolades, including the “EVO ICL Outstanding Academic Contribution Award,” “EVO ICL 5,000-Case Expert,” and “EVO ICL Scientific Talent Award.”

Her inclusion among China's first wave of EVO+ICL (V5) technology-certified practitioners stems from her forward-thinking approach to cutting-edge technologies and extensive expertise. In fact, even during the clinical application phase of EVO+ICL (V5) in Hong Kong and the Boao Pilot Zone, Director Chen Xiaobei closely monitored and actively participated in the early implementation of this technology. She personally traveled to Boao to perform V5 surgeries and, based on her full recognition of the technology's clinical efficacy, recommended patients in need to seek treatment at Aier Hong Kong or Boao, accumulating invaluable firsthand experience.

Guided by the commitment to “bring new technologies to Dongguan at the earliest opportunity,” and leveraging the international platform and resource-sharing advantages of the Aier Eye Hospital Group, the refractive team at Dongguan Aier Eye Hospital gains early access to cutting-edge global technologies. Following the nationwide launch of EVO+ICL (V5) in January this year, Director Chen Xiaobei swiftly obtained certification and performed the first implantation, becoming a key driver in bringing this innovative technology to local patients.

Director Chen Xiaobei Awarded EVO+ICL (V5) Surgical Certification by STAAR Surgical, USA

Continuous Technological Advancement

Building a “Fully Customized” Refractive Surgery System

From performing Dongguan's first ICL surgery in 2015 to pioneering the city's first all-optical sculpting procedure and first domestically produced Longjing® PR intraocular lens implantation in recent years, and leading the way in July 2025 by introducing the next-generation Zeiss VISUMAX 800 robotic femtosecond laser system to complete China's first batch and Dongguan's inaugural robotic SMILE pro surgeries, Dongguan Aier Eye Hospital's Refractive Surgery Department has consistently led the region in refractive technology, continuously introducing internationally advanced techniques locally. This has progressively established a “fully customized” myopia correction solution matrix, expanding high-quality options for patients.

Under the leadership of Director Chen Xiaobei, the department remains committed to delivering “high-definition visual solutions synchronized with global standards.” Moving forward, the hospital will leverage Aier Eye Hospital Group's global resource platform and scientific research capabilities to accelerate the clinical translation and application of cutting-edge ophthalmic technologies. Through safer, more precise, and personalized diagnostic and therapeutic services, it is dedicated to safeguarding the visual health of Dongguan residents and advancing refractive care in the city to new heights.